Buscar

01/01/2023 External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort
Van Straalen K.R., Tzellos T., Alavi A., Benhadou F., Cuenca-Barrales C., Daxhelet M., Daoud M., Efthymiou O., Giamarellos-Bourboulis E.J., Guillem P., Gulliver W., Jemec G.B.E., Katoulis A., Koenig A., Lazaridou E., Lowes M.A., Marzano A.V., Matusiak L., Molina-Leyva A., Moltrasio C., Pinter A., Potenza C., Prens E.P., Romaní J., Saunte D.M., Sayed C., Skroza N., Stergianou D., Szepietowski J.C., Trigoni A., Vilarrasa E., Kyrgidis A., Zouboulis C.C., Van Der Zee H.H.. External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort. DERMATOLOGY. 2023; 239(3)DOI:10.1159/000528968. PMID:36630943. IF:3.000(Q2/4D).
01/01/2023 Chronic prurigo: Insufficient disease control in spite of high healthcare usage
Pereira M.P., Weisshaar E., Halvorsen J.A., Wallengren J., Legat F.J., Garcovich S., Savk E., Reich A., Bozek A., Lvov A., Bobko S., Metz M., Streit M., Misery L., Brenaut E., Serra-Baldrich E., Gonçalo M., Szepietowski J.C., Augustin M., Nau T., Zeidler C., Ständer S.. Chronic prurigo: Insufficient disease control in spite of high healthcare usage. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(6)DOI:10.1111/jdv.18903. PMID:36682045. IF:8.500(Q1/1D).
01/01/2023 Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
Blauvelt A., Thyssen J.P., Guttman-Yassky E., Bieber T., Serra-Baldrich E., Simpson E., Rosmarin D., Elmaraghy H., Meskimen E., Natalie C.R., Liu Z., Xu C., Pierce E., Morgan-Cox M., Garcia Gil E., Silverberg J.I.. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(6)DOI:10.1093/bjd/ljad022. PMID:36994947. IF:11.000(Q1/1D).
01/01/2023 [Translated article] Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts [Abordaje común del paciente con psoriasis y riesgo de esteatosis hepática metabólica: recomendaciones de un grupo de expertos multidisciplinar]
Carrascosa J.M., Vilarrasa E., Belinchón I., Herranz P., Crespo J., Guimerá F., Olveira A.. [Translated article] Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts [Abordaje común del paciente con psoriasis y riesgo de esteatosis hepática metabólica: recomendaciones de un grupo de expertos multidisciplinar]. Actas Dermo-Sifiliograficas. 2023; 114(5)DOI:10.1016/j.ad.2023.04.013. PMID:37068635. IF:(Q/D).
01/01/2023 Reply to: “Comment on ‘Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: An observational study to assess prevalence and causes’”
Schneller-Pavelescu L., Vergara-de Caso E., Martorell A., Romaní J., Lázaro M., Vilarrasa E., Díaz-Ley B., Vázquez-Osorio I., Segura Palacios J.M., Azaña J.M., González-López M.A., Cañueto J., Molina-Leyva A., Leiva-Salinas M., Navarro-Triviño F.J., Sánchez-Payá J., Pascual J.C.. Reply to: “Comment on ‘Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: An observational study to assess prevalence and causes’”. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 88(5)DOI:10.1016/j.jaad.2019.03.006. PMID:30872153. IF:12.800(Q1/1D).
01/01/2023 Skin cancer special issue in Skin Health and Disease
Yélamos O., Geller S., Tokez S.. Skin cancer special issue in Skin Health and Disease. Skin Health And Disease. 2023; 3(2)DOI:10.1002/ski2.224. PMID:37013119. IF:(Q/D).
01/01/2023 [Translated article] BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis [Tumor melanocítico inactivado a BAP1: claves para su diagnóstico dermatoscópico]
Fustà-Novell X., García-Herrera A., Yélamos O.. [Translated article] BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis [Tumor melanocítico inactivado a BAP1: claves para su diagnóstico dermatoscópico]. Actas Dermo-Sifiliograficas. 2023; 114(2)DOI:10.1016/j.ad.2022.11.008. PMID:36464005. IF:(Q/D).
01/01/2023 The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease
Olveira A., Augustin S., Benlloch S., Ampuero J., Suárez-Pérez J.A., Armesto S., Vilarrasa E., Belinchón-Romero I., Herranz P., Crespo J., Guimerá F., Gómez-Labrador L., Martín V., Carrascosa J.M.. The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease. Life-Basel. 2023; 13(2)DOI:10.3390/life13020419. PMID:36836776. IF:3.200(Q1/3D).
01/01/2023 Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
Simpson E.L., Pink A.E., Blauvelt A., Gooderham M., Armstrong A.W., Worm M., Katoh N., Peris K., Puig L., Barbarot S., Mark T., Steffensen L.A., Tindberg A.-M., Wollenberg A.. Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2023; 24(6)DOI:10.1007/s40257-023-00806-3. PMID:37682422. IF:8.600(Q1/1D).
01/01/2023 Race, Ethnicity, and Ancestry: A Short Review and Proposal for Consistent Classifications in Dermatology
Puig L.. Race, Ethnicity, and Ancestry: A Short Review and Proposal for Consistent Classifications in Dermatology. Actas Dermo-Sifiliograficas. 2023; 114(10)DOI:10.1016/j.ad.2023.07.013. PMID:37482290. IF:(Q/D).
01/01/2023 The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study
Rivera-Díaz R., Pozo T., Alfageme F., Díaz Ley B., Osorio G.F., Chico R., Vilarrasa E., Silvente C., Ciudad Blanco C., Romaní J., Martorell A., Fernández P., Romero Ferreiro C., Molina Leyva A.. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study. Actas Dermo-Sifiliograficas. 2023; 114(9)DOI:10.1016/j.ad.2023.06.013. PMID:37331620. IF:(Q/D).
01/01/2023 Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results
Pereyra-Rodriguez J.J., Herranz P., Figueras-Nart I., Perez B., Elosua M., Munera-Campos M., Melgosa-Ramos J., Zaragoza V., Silvestre J.F., Campos-Domínguez M., Guilabert A., Miquel J., Alcantara-Luna S., de la Cueva P., Serra-Baldrich E., Armario-Hita J.C.. Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. 2023; 33(3)DOI:10.18176/jiaci.0831. PMID:35671128. IF:6.700(Q1/2D).
01/01/2023 Cardiovascular Screening Practices and Statin Prescription Habits in Patients with Psoriasis among Dermatologists, Rheumatologists and Primary Care Physicians
Berna-Rico E., ABBAD-JAIME DE ARAGON C., Garcia-Aparicio Á., Palacios-Martinez D., Ballester-Martínez A., Carrascosa J.-M., DE LA CUEVA P., Anton C., Azcarraga-Llobet C., Garcia-Mouronte E., DE NICOLAS-RUANES B., Puig L., Jaen P., Mehta N.N., Gelfand J.M., Gonzalez-Cantero Á.. Cardiovascular Screening Practices and Statin Prescription Habits in Patients with Psoriasis among Dermatologists, Rheumatologists and Primary Care Physicians. ACTA DERMATO-VENEREOLOGICA. 2023; 103DOI:10.2340/actadv.v103.5087. PMID:36987537. IF:3.500(Q1/3D).
01/01/2023 Reflectance Confocal Microscopy Terminology in Spanish: A Delphi Consensus Study.
Abarzua-Araya A, Bañuls J, Cabo H, Carrera C, Gamo R, González S, Jaimes N, Navarrete-Dechent C, Pérez Anker J, Roldán-Marín R, Segura S, Yélamos O, Puig S, Malvehy J. Reflectance Confocal Microscopy Terminology in Spanish: A Delphi Consensus Study.. Actas Dermo-Sifiliograficas. 2023; 115(3)DOI:10.1016/j.ad.2023.10.014. PMID:37890615. IF:(Q/D).
01/01/2023 Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain.
Artime E, Serra E, Mert C, Díaz-Cerezo S, Huete T, Hernández-Subirá I, Lledo-Bryant L, Sicras-Mainar A. Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain.. Actas Dermo-Sifiliograficas. 2023; 114(1)DOI:10.1016/j.ad.2022.08.015. PMID:36030827. IF:(Q/D).
01/01/2023 Tratamiento comparativo de lesiones mucocutáneas en pacientes con telangiectasia hemorrágica hereditaria con láser dual secuencial de colorante pulsado y neodimio: itrio-aluminio-granate versus neodimio: itrio-aluminio-granate solo: un estudio controlado aleatorizado doble ciego con evaluación de la calidad de vida
Cubiró X., Garcia-Melendo C., Morales-Munera C.E., Riera-Mestre A., Torres-Iglesias R., Villanueva B., Puig L., Baselga E.. Tratamiento comparativo de lesiones mucocutáneas en pacientes con telangiectasia hemorrágica hereditaria con láser dual secuencial de colorante pulsado y neodimio: itrio-aluminio-granate versus neodimio: itrio-aluminio-granate solo: un estudio controlado aleatorizado doble ciego con evaluación de la calidad de vida. Actas Dermo-Sifiliograficas. 2023; 115(3)DOI:10.1016/j.ad.2023.10.017. PMID:37913989. IF:(Q/D).
01/01/2023 Corrigendum: The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases(Front. Immunol., (2023), 14, (1191782), 10.3389/fimmu.2023.1191782)
Navarro-Compán V., Puig L., Vidal S., Ramírez J., Llamas-Velasco M., Fernández-Carballido C., Almodóvar R., Pinto J.A., Galíndez-Aguirregoikoa E., Zarco P., Joven B., Gratacós J., Juanola X., Blanco R., Arias-Santiago S., Sanz J.S., Queiro R., Cañete J.D.. Corrigendum: The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases(Front. Immunol., (2023), 14, (1191782), 10.3389/fimmu.2023.1191782). Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1332177. PMID:. IF:(Q/D).
30/12/2022 The Benefits of Early versus Late Therapeutic Intervention in Fabry Disease.
Furlano M, Ars E, Matamala A, Brossa V, Martí J, Del Prado-Venegas M, Crespi J, Roe E, Torra R. The Benefits of Early versus Late Therapeutic Intervention in Fabry Disease.. Case Reports In Genetics. 2022; 2022DOI:10.1155/2022/3208810. PMID:36619006. IF:(Q/D).
01/06/2025 Baseline Characteristics and Treatment Patterns of Patients with Atopic Dermatitis Treated with Oral Systemic Therapies: An Interim Analysis of the AD-REAL Study
Augustin, M, Serra-Baldrich, E, Seneschal, J, Grond, S, Lampropoulou, A, Elrayes, M, Ogwu, S, de la Torre, I, Bewley, A, Pinter, A. Baseline Characteristics and Treatment Patterns of Patients with Atopic Dermatitis Treated with Oral Systemic Therapies: An Interim Analysis of the AD-REAL Study. ADVANCES IN THERAPY. 2025; 42(6)DOI:10.1007/s12325-025-03137-3. PMID:40192965. IF:4.000(Q1/3D).
01/06/2025 Cholinergic Pruritus as an Early Sign of Essential Thrombocythemia With Therapeutic Response to Ruxolitinib
Mateu-Arrom, L, Serra-Baldrich, E, Puig, L. Cholinergic Pruritus as an Early Sign of Essential Thrombocythemia With Therapeutic Response to Ruxolitinib. Actas Dermo-Sifiliograficas. 2025; 116(6)DOI:10.1016/j.ad.2023.09.035. PMID:39947585. IF:(Q/D).